根治性前列腺切除术在盆腔淋巴结受侵及转移性前列腺癌中的应用及现状

赵炎; 梁杰; 林英立; 戚景光; 杨宁

doi:10.13201/j.issn.1001-1420.2019.12.021

根治性前列腺切除术在盆腔淋巴结受侵及转移性前列腺癌中的应用及现状

- 江苏大学附属徐州医院徐州市肿瘤医院泌尿外科(江苏徐州, 221005)

详细信息

通讯作者: 赵炎,E-mail:529735655@qq.com

中图分类号: R737.25

收稿日期: 2018-05-23

Application and present situation of radical prostatectomy in patients with pelvic lymph node positive disease and metastatic prostate cancer

- Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, Jiangsu, 221005, China

More Information

Corresponding author: ZHAO Yan, E-mail: 529735655@qq.com

Received Date: 23 May 2018

摘要

摘要: 前列腺癌为临床常见泌尿系肿瘤，该疾病具有很高的侵袭性，大多数前列腺癌患者在初诊时已经出现转移。传统观念认为盆腔淋巴结受侵及转移性前列腺癌患者应当选择全身系统性治疗，不推荐根治性前列腺切术。近年来，随着技术手段的进步，经过筛选，一些患者接受了根治手术并达到了良好的生存获益效果。根治性前列腺切术应用于盆腔淋巴结受侵及转移性前列腺癌这一新的理念逐渐被临床医师所重视。为此，本文对根治性前列腺切除术在盆腔淋巴结受侵及转移性前列腺癌中的应用及现状作一综述。
- 根治性前列腺切除术 /
- 前列腺癌 /
- 转移性 /
- 盆腔淋巴结受侵
Abstract: Prostate cancer is a common urinary system disease and a very aggressive malignancy. Most patients are presented with metastasis at diagnosis. Traditionally, systematic treatment was recommended in patients with pelvic lymph node positive disease and metastatic prostate cancer. Radical prostatectomy was discouraging. In recent years, with the development of treatment method, some cases underwent radical prostatectomy and achieved positive outcomes. Radical prostatectomy used in patients with pelvic lymph node positive disease and metastatic prostate cancer, a new concept, is gaining more and more attention. Thus, the purpose of this review was to summarize the current knowledge on radical prostatectomy in this setting.
- radical prostatectomy /
- prostate cancer /
- metastatic /
- pelvic lymph node positive

HTML全文

参考文献(29)

[1]	Miller K D, Siegel R L, Lin C C, et al.Cancer treatment and survivorship statistics, 2016[J].CA Cancer J Clin, 2016, 66(4):271-289.
[2]	Xue J, Qin Z, Cai H, et al.Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer:a meta-analysis and trial sequential analysis[J].Oncotarget, 2017, 8(14):23322-23336.
[3]	Gakis G, Boorjian S A, Briganti A, et al.The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer:a systematic review of the literature[J].Eur Urol, 2014, 66(2):191-199.
[4]	Seisen T, Vetterlein M W, Karabon P, et al.Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis[J].Eur Urol, 2017.
[5]	Fahmy O, Khairul-Asri M G, Hadi S H S M, et al.The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer:A Systematic Review and Meta-Analysis[J].Urol Int, 2017, 99(3):249-256.
[6]	Bookman M A.Optimal primary therapy of ovarian cancer[J].Ann Oncol, 2016, 27 Suppl 1:i58-i62.
[7]	Flanigan R C, Mickisch G, Sylvester R, et al.Cytoreductive nephrectomy in patients with metastatic renal cancer:a combined analysis[J].J Urol, 2004, 171(3):1071-1076.
[8]	Culp S H, Schellhammer P F, Williams M B.Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor?A SEER-based study[J].Eur Urol, 2014, 65(6):1058-1066.
[9]	Engel J, Bastian P J, Baur H, et al.Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer[J].Eur Urol, 2010, 57(5):754-761.
[10]	Verhagen P C, Schröder F H, Collette L, et al.Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy?A systematic review[J].Eur Urol, 2010, 58(2):261-269.
[11]	Bader P, Burkhard F C, Markwalder R, et al.Disease progression and survival of patients with positive lymph nodes after radical prostatectomy.Is there a chance of cure?[J].J Urol, 2003, 169(3):849-854.
[12]	Cornford P, Bellmunt J, Bolla M, et al.EAU-ESTRO-SIOG Guidelines on Prostate Cancer.Part Ⅱ:Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer[J].Eur Urol, 2017, 71(4):630-642.
[13]	龚玉雯, 庞阳阳, 景锁世, 等.转移性去势抵抗性前列腺癌的治疗顺序与策略[J].临床泌尿外科杂志, 2016, 31(10):953-959.
[14]	王艳龙, 杜浩, 任宇, 等.减瘤性前列腺切除术治疗前列腺癌骨转移患者的研究进展[J].中华泌尿外科杂志, 2017, 38(1):72-74.
[15]	Predina J D, Kapoor V, Judy B F, et al.Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness[J].J Hematol Oncol, 2012, 5:34.
[16]	Tovar Sepulveda V A, Falzon M.Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways[J].Regul Pept, 2002, 105(2):109-120.
[17]	Ongkeko W M, Burton D, Kiang A, et al.Parathyroid hormone related-protein promotes epithelial-to-mesenchymal transition in prostate cancer[J].PLoS One, 2014, 9(1):e85803.
[18]	Qin X J, Ma C G, Ye D W, et al.Tumor cytoreduction results in better response to androgen ablation——a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer[J].Urol Oncol, 2012, 30(2):145-149.
[19]	Sheng M X, Wan L L, Liu C M, et al.Cytoreductive cryosurgery in patients with bone metastatic prostate cancer:A retrospective analysis[J].Kaohsiung J Med Sci, 2017, 33(12):609-615.
[20]	Löppenberg B, Dalela D, Karabon P, et al.The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis:A National Cancer Data Base Analysis[J].Eur Urol, 2017, 72(1):14-19.
[21]	Heidenreich A, Pfister D, Porres D.Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases:results of a feasibility and case-control study[J].J Urol, 2015, 193(3):832-838.
[22]	Fossati N, Trinh Q D, Sammon J, et al.Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer:a SEER-based study[J].Eur Urol, 2015, 67(1):3-6.
[23]	Moschini M, Morlacco A, Kwon E, et al.Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis[J].Prostate Cancer Prostatic Dis, 2017, 20(1):117-121.
[24]	Steuber T, Berg K D, Røder M A, et al.Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis?Results from a Prospective Case-Control Study[J].Eur Urol Focus, 2017, 3(6):646-649.
[25]	Wang Y, Qin Z, Wang Y, et al.The role of radical prostatectomy for the treatment of metastatic prostate cancer:a systematic review and meta-analysis[J].Biosci Rep, 2018.
[26]	Satkunasivam R, Kim A E, Desai M, et al.Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer:A SEER-Medicare Analysis[J].J Urol, 2015, 194(2):378-385.
[27]	Antwi S, Everson T M.Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis:A population-based, propensity score analysis[J].Cancer Epidemiol, 2014, 38(4):435-441.
[28]	Kim D K, Parihar J S, Kwon Y S, et al.Risk of complications and urinary incontinence following cytoreductive prostatectomy:a multi-institutional study[J].Asian J Androl, 2018, 20(1):9-14.
[29]	Poelaert F, Verbaeys C, Rappe B, et al.Cytoreductive Prostatectomy for Metastatic Prostate Cancer:First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer(LoMP) Trial[J].Urology, 2017, 106:146-152.